Last reviewed · How we verify

NCT07208721

The Key to Emotional Balance

Not yet recruiting NA Last updated 6 October 2025
What this trial tests

NA trial testing The Key to Emotional Balance in The Key to Emotional Balance in 74 participants. Not yet recruiting.

Timeline
1 October 2025
Primary endpoint
1 June 2026
1 September 2026

Quick facts

Lead sponsorTC Erciyes University
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment74
Start date1 October 2025
Primary completion1 June 2026
Estimated completion1 September 2026

Drugs / interventions tested

Conditions studied

Sponsor

TC Erciyes University

Who can join

Adults 18 to 65, any sex, with The Key to Emotional Balance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized controlled experimental study aimed to evaluate the effects of the Key to Emotional Balance (KBA) psychoeducational program, based on the Balance Model of Positive Psychotherapy (PPT), on indicators of emotion regulation difficulties, recovery, and purpose in life in adults with bipolar disorder. Intervention and control groups (n=37 each; total n=74) will be formed through simple random assignment. The intervention will consist of eight individual sessions, each lasting 40-50 minutes. Data will be collected using the Difficulty in Emotion Regulation, Recovery Assessment Scale, and the Life Goals Scale in the Context of PPT. Measurements will be conducted as a pretest and posttest.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other TC Erciyes University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07208721.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing